[Progression of lesions of the arterial wall evaluated by ultrasonic biopsy in asymptomatic subjects and in diabetic and hyperlipidemic patients treated with bezafibrate. A 4-year follow-up].
Non-invasive arterial ultrasonic biopsy (UB) has been used to evaluate and follow-up arterial wall changes in four years in asymptomatic subjects, hyperlipidemics and diabetics. Both groups of patients were randomised in a treatment group (bezafibrate 400 mg daily) and in a control group. The rate of progression (ROP) into the next higher UB class was recorded by UB scans repeated every six months. In diabetics and hyperlipidemics the rate of progression (ROP, namely the percent of patients progressing to the next class) was significantly higher than the ROP in the asymptomatic subjects. However in the bezafibrate group the ROP was significantly lower than that observed in the controls. As each UB class corresponds to different levels of risks of occult coronary ischemia and cardiovascular events in the following four years, the reduction of ROP with bezafibrate was an important and positive achievement.
Cesarone
M R
MR
Clinica Cardiovascolare, Università G. D'Annunzio, Chieti.
Laurora
G
G
De Sanctis
M T
MT
Pomante
P
P
Belcaro
G
G
D000328:Adult; D000368:Aged; D001158:Arteries / Q000000981:diagnostic imaging* / Q000473:pathology*; D001629:Bezafibrate / Q000008:administration & dosage / Q000627:therapeutic use*; D001706:Biopsy; D002784:Cholesterol / Q000097:blood; D003920:Diabetes Mellitus / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D013997:Time Factors; D014280:Triglycerides / Q000097:blood; D014463:Ultrasonography
D014280:Triglycerides; D002784:Cholesterol; D001629:Bezafibrate
Progressione delle lesioni della parete arteriosa valutate con biopsia ultrasonica in soggetti asintomatici ed in diabetici ed iperlipidemici trattati con bezafibrato. Follow-up di 4 anni.